PeopleBio, Inc.: debt-to-equity, ROE and more
KOSDAQ, Legal name PeopleBio, Inc.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 55.7%
- Equity ratio
- 64.2%
- ROE
- -59.2%
- Op. margin
- -293.9%
- Rev. growth
- -23.6%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 170.0% | 37.0% | -26.0% | -1,253.8% | n/a |
| FY2022 consolidated | 614.3% | 14.0% | n/a | -263.2% | 670.2% |
| FY2023 consolidated | 40.3% | 71.3% | n/a | -342.4% | 0.2% |
| FY2024 consolidated | 255.3% | 28.1% | n/a | -308.2% | -16.2% |
| FY2025 consolidated | 55.7% | 64.2% | -59.2% | -293.9% | -23.6% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩577.1M | ₩4.4B | ₩4.5B | ₩3.7B | ₩2.9B |
| Operating profit | -₩7.2B | -₩11.7B | -₩15.2B | -₩11.5B | -₩8.4B |
| Pre-tax income | -₩4.9B | -₩15.0B | -₩17.4B | -₩12.2B | -₩12.5B |
| Net income | -₩4.9B | 0 | 0 | 0 | -₩16.9B |
| Total assets | ₩51.3B | ₩42.3B | ₩27.6B | ₩27.1B | ₩44.6B |
| Total liabilities | ₩32.3B | ₩36.4B | ₩7.9B | ₩19.5B | ₩16.0B |
| Total equity | ₩19.0B | ₩5.9B | ₩19.7B | ₩7.6B | ₩28.6B |
| Paid-in capital | ₩5.9B | ₩6.2B | ₩10.9B | ₩10.9B | ₩10.9B |
| Debt/equity (source value) | 170.0% | 614.3% | 40.3% | 255.3% | 55.7% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2002-09-09
- Listed
- 20/10/19
- Employees
- 43
- Auditor
- 다산회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101112606171
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 피플바이오Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.